Genmab A/S

Genmab A/S

GNMSF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$30.87B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Genmab A/SGenmab A/S42.8-14%3.10.8

Earnings Call Q3 2026

November 5, 2026 - AI Summary

Strong financial momentum (good): First nine months of 2026 revenue grew 22% YoY (to about $4.3B–$4.5B full-year run-rate), driven mainly by DARZALEX (+19% YoY) and EPKINLY (+47% YoY net product sales); the rest of the portfolio also rose 30% YoY. Adjusted operating profit up 9%—they emphasize they can increase investment while maintaining profitability.
Clear 2026 guidance maintained with an upside to revenue (good + forecast): Company is maintaining full-year guidance: Revenue ~ $4.325B–$4.525B (midpoint ~19% growth), and they now expect revenue toward the upper end of the range. Operating expense guidance unchanged: ~$2.81B–$2.95B (midpoint ~$2.88B). Adjusted operating profit guidance ~ $1.065B–$1.35B (midpoint > $1.2B), with expectation profit above midpoint given revenue outlook. Q4 OpEx expected to step up significantly (manufacturing, clinical development, launch readiness).
Unprecedented Phase III wins in Oct (surprising + opportunity): Management highlighted three major Phase III readouts with potential to change standards of care: - EPKINLY (epcoritamab): EPCORE DLBCL-2 met PFS endpoint HR 0.49—positioned as potential shift in frontline DLBCL after long-standing R-CHOP. - Rina-S: RAINFOL-02 met PFS HR 0.29 (and OS as key secondary) in platinum-resistant ovarian cancer, aiming for best-in-class/broadest-in-class across gyn-onc. - Petosemtamab: LiGeR-HN1 met dual endpoints (OS HR 0.5 plus ORR) in first-line head & neck; next Phase III (LiGeR-HN2) expected Q1 2027; also expanding into colorectal.

Exclusive for Stockcircle Pro members

Sign upSign Up
$54.10

Current Fair Value

89.3% downside

Overvalued by 89.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$30.87 Billion
Enterprise Value$34.23 Billion
Earnings per Share$16.04
Beta0.66
Outstanding Shares61,290,323

Return

Return on Equity14.14%ROE
Return on Assets6.92%
Return on Invested Capital22.69%

Valuation & Multiples

P/E Ratio42.8P/E Ratio
PEG-290.86PEG
Price to Sales3.11Price to Sales
Price to Book Ratio4.89Price to Book Ratio
Enterprise Value to Revenue3.44
Enterprise Value to EBIT12.97
Enterprise Value to Net Income38
Total Debt to Enterprise0.15
Debt to Equity0.82Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$5.58
Est. $3.49
Revenue
$1.19 B
Est. $1.20 B

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
$2.12
Consensus analyst estimate
Revenue Estimate
$1.25 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Genmab

3,029 employees
CEO: Jan van de Winkel

Genmab A/S, established in 1999 and headquartered in Copenhagen, Denmark, is a biotechnology firm specializing in the development of antibody therapeutics for cancer and various other medical conditions, primarily operating from its Dani...